After infusion, the growth of KE4 tumors (MAGE-A4+, HLA-A*2402+) was specifically inhibited, while the tumor size of QG56 tumors (MAGE-A4+, HLA-A*2402−) was not changed, indicating that the modified T cells specifically killed their HLA matching KE4 tumors. This evidence concerns the gene MAGEA4 and neoplasm.